Table 2.
Characteristics of UK biobank participants.
| COVID-19 | Controls | p $ | |
|---|---|---|---|
| N | 436 | 356,799 | |
| Males, n (%) | 249 (57) | 161,179 (45) | <0.001 |
| Age, median (IQR), y∧ | 70 (16) | 69 (13) | <0.001 |
| Deaths, n (%)* | 117 (27) | 688 (0.002) | <0.001 |
| Age at death, median (IQR), y | 75 (8) | 74(8) | 0.75 |
| Body Mass Index, median (IQR) | 29.1 (6.2) | 27.3 (5.7) | <0.001 |
| Diabetes, n (%) | 38 (8.7) | 15,815 (4.4) | <0.001 |
| Asthma, n (%) | 65 (15) | 41,508 (12) | 0.015 |
| COPD, n (%) | 42 (9.6) | 8,371 (2.4) | <0.001 |
| Interstitial lung disease, n (%) | 7 (1.6) | 1,262 (0.3) | <0.001 |
N, number; y, years; IQR, inter quartile range; COPD, chronic obstructive pulmonary disease; Diabetes, any definition of diabetes.
$
Linear regression associations observed using available data in white European covid cases vs. controls, adjusted for age and sex where relevant.
∧
=age at 15/03/2020
*
Deaths were those that occurred between 15/03/20 and 31/5/20 only.